Dr. Paul Sax discusses why a new “best in class” drug for HIV has an uncertain role in
HIV and ID Observations.
NNRTI-based (non-nucleoside reverse transcriptase inhibitors) regimens have had the greatest impact in years of life saved from antiretroviral therapy, Dr. Paul Sax asserts. In the latest HIV and ID Observations, he discusses the newest drug approved in this class.
Want to see more from NEJM Journal Watch? Register here.